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SUMMARY
The use ofcentral venous catheters in patients suffering from haematological
disorders has brought enormous benefits, but has been associated with an
increase insepticaemia. Wehavereviewedsepticandothercomplications in43
patients who received one ofthree different forms ofcentral venous catheters
(type A - Hickman®, type B - Portacath®, type C - Pasport®) during 1991. All
complications were reviewed up to 18 months following insertion. The total
complication rate was 31% (0.97 per 100 catheter days), and the total sepsis
complication rate was 18.8% (0.49per 100catheterdays). TypeA catheters had
thegreatestsepsiscomplication rateof29.5% (0.84per 100catheterdays), with
type B 15% (0.39per100catheterdays) and type C9.9% (0.32per100catheter
days). Prophylactic antibiotics on the day ofcatheter insertion did not reduce
the sepsis rate orprolong catheter survival.
INTRODUCTION
Many of the patients suffering from haematological malignancies benefit from
the insertion of indwelling central venous lines as these provide reliable, pain
free access for intravenous therapy (chemotherapy, intravenous fluids, blood
transfusions etc ), venous sampling and total parenteral nutrition.' 2 Three
different central venous catheters are inserted in our unit. Type A (Hickman®)
lines are hollow silicone-rubber catheters which have central venous access
through the internaljugular vein and exit, after a subcutaneous course, through
the anterior chest area. Type B (Portacath®) catheters also gain central venous
access through the internal jugular vein but, instead of coming out through the
skin, end with a subcutaneous reservoir in the lower anterior chest area. This
requires to be "plumbed in" using a specially designedneedle priorto use. Type
C (Pasport®) catheters also have a subcutaneous reservoir but this lies in the
forearm and the line gains venous access through the antecubital route. Type
A lines are generally inserted for those patients about to embark on intensive
chemotherapy, including autologous bone marrow transplantation, while type
B and C lines are reserved for those receiving intermittent chemotherapy or
rarely in those who are judged incapable of looking after a type A catheter.
Patients find these catheters of great benefit and the vast majority master the
techniques of long term catheter care in the case of the type A line. Both the
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type B and C catheters have resulted in increasing numbers of patients being
able to have chemotherapy at home via a controlled pump infusion. However,
use of the catheters has been associated with an increased incidence of
septicaemic episodes.'
The aim of our study was to evaluate the complication rate (both septic and
otherwise) in the three different central lines inserted in haematology patients
during the year of 1991, following all these patients over an 18 month period
from the date of insertion.
PATIENTS AND METHODS
Patient Population
This was a retrospective study reviewing the medical records ofall the patients
who hadType A, B or C line insertions during the year 1991. The patients were
followed for a maximum period of 18 months from the date of line insertion.
Forty-three patients had line insertionsduring the year-their clinical diagnoses
are listed in Table 1. There were 21 males and 22 females, mean age 41.7 ±
15.3 years ( 1 SD). It became the policy of the unit to give routine antibiotic
prophylaxis to all patients undergoing central catheter insertions in May 1991-
this consisted of teicoplanin 200mg iv 2 hours prior to surgery and a further
200mg iv at induction of anaesthesia. The basis for this regime was to attempt
to achieve maximal plasma and tissue concentrations ofteicoplanin atthe time
ofline insertion. Two groups ofpatients resulted -those who received antibiotic
prophylaxis and those who did not prior to the establishment of this policy.
TABLE I
Clinical diagnoses ofpatients in study.
Diagnosis Number ofpatients
Acute myeloid leukaemia 2
Acute lymphatic leukaemia 6
Hodgkins disease 3
Non-Hodgkins lymphoma 9
Multiple myeloma 19
Plasma cell leukaemia I
Synovial cell sarcoma 1
Myelodysplasia 1
Osteosarcoma 1
Catheter insertion
There was no formal policy for the type of catheter inserted but, in general,
those who were to receive intensive chemotherapy, including autologous
marrow transplantation, had a type A catheter inserted. Type C catheters were
reserved for those with reasonable venous access in the arms, especially young
females where the cosmetic acceptability ofthistype ofline was beneficial. The
technique of catheter insertion was not specified by a predetermined protocol
but all were inserted by the same surgical team using a strict aseptic technique
similar to that described by Heimbach and Ivey.' All the patients had general
anaesthesia with the exception of 3 patients who had local anaesthesia.
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Patients with low platelet counts (<50 x 109/L) were given platelet transfusions
before and during the procedure.
Following the procedure wound care was the responsibility ofthe nursing staff
intheward.TypeBandCcathetersdidnotrequireintensivewoundmanagement
and clips were generally removed after 7 days. However with type A catheters
management involvedcleansingoftheexitsiteonadailybasiswithchlorhexidine
and povidone iodine solutions. The catheter was flushed daily with 10 mls of
heparinised saline when the line was not in use. All of the patients were given
supervised training by nursing staff with regard to this procedure, and were
subsequently able to perform this themselves at home.
Review ofComplications
Septicandothercomplications (i.e. thrombosis, extravasationofchemotherapy,
malposition of catheter tip, accidental withdrawal and haemorrhage) were
reviewed over an 18 month period (maximum) from the date ofinsertion ofthe
catheter. For this study all septic episodes were classified into three separate
categories. 1. Catheter related septicaemia: an episode of microbiologically
proven septicaemia inculturefromthecatheterorperipheral blood, orbacterial
growth from the catheter tip. 2. External exit site infection: indicated by either
erythema, tenderness, palpable thrombosed vein or pus around the site. This
was subsequently confirmed by positive swab culture. 3. Clinically suspicious
catheter infection: fever and malaise with no apparent clinical signs of line
infection such as erythema ortenderness, no localising signs ofother infection
and no positive blood cultures, but responding to either teicoplanin or
vancomycin.
Cumulative catheter survival was calculated using Kaplan-Meiersurvival plots,
and the log-rank test was used to compare differences in survival between the
three lines. Deaths occurring unrelatedtoline complications, patientswith lines
in situ at 18 months or with lines electively removed because treatment had
finished were "censored" in the analysis. The chi-squared (X2) test, with Yates
correction, was usedtoassess forstatistical differences betweentheoccurrence
of septic episodes in those who had received prophylactic antibiotics and in
those who had not.
RESULTS
Thirteen patients received a type A (Hickman®) catheter, 20 patients a type B
(Portacath®) catheter and ten patients a type C (Pasport®) catheter. Four
patients received a second type A catheter following removal of the initial
catheter and I patient required insertion of a second type C catheter following
removal ofthefirst, giving atotalof48 catheterinsertions. Thefollowing results
refer to the complications in catheters as opposed to patient numbers. Overall
the cumulative catheter survival was 73.1% at six months and 66.9% at both 12
and 18 months. There was a cumulative total of 12,734 catheter days, a total
complication rate of 31% or 0.97 per 100 catheter days and a total septic
complication rate of 18.8% or 0.49 per 100 catheter days. There were no
statistically significant differences in the cumulative survival of the three
different lines up to six months or between type B and C catheters up to 18
months (log rank test). Results for the individual catheters are summarised in
Table 2.
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TABLE 2
Summary ofresults for three different lines.
Type A Type B Type C
Number inserted 17 20 11
Cumulative total days 2757 6857 3120
Complication free 10 (59%) 15 (75%) 8 (73%)
Sepsis complication 5 (29.5%) 3 (15%) 1 (9%)
(per 100 catheter days) 0.84 0.39 0.32
Non-Sepsis complication 2 (11.5%) 2 (10%) 2 (18%)
Cumulative catheter survival
6 months 63.7% 78.6% 79.5%
12 months 78.6% 66.3%
18 months - 78.6% 66.3%
With type A catheters, four patients developed catheter related septicaemia,
necessitating removal ofthe lines following failure of antibiotic therapy. These
were subsequently replaced and no further complications occurred with the
new lines. One other patient had a clinically suspicious catheter infection that
responded to teicoplanin. All of the patients suffering from acute leukaemia
(n=8) received type Acatheters and itwas fourofthese patientswhodeveloped
the catheter related septicaemia. The other type A catheters were inserted in
patients with relapsed non-Hodgkins lymphoma (n=4) and Hodgkins disease
(n=1) who required marrow ablative chemotherapy. Three patients died with
their lines in situ from causes unrelated to catheter sepsis. In the remaining
patients catheters were electively removed following treatment, with all of the
lines having been removed (or the patient having died) after six months. The
only non-septic complications seen were two lines that were accidentally
withdrawn.
With type B catheters, three patients developed catheter related septicaemia
but all responded to intravenous antibiotics. Eight patients died with their lines
in situ from causes unrelated to catheter.sepsis, the others surviving the 18
month study period. The non-septic complications were one catheter induced
subclavian vein thrombosis and one extravasation of chemotherapy.
With type C catheters, there was no catheter related septicaemia, but one
episode ofexit site infection occurred that responded to antibiotics. Four ofthe
patients died with their lines in situ from causes unrelated to catheter sepsis,
the others surviving at 18 months. The non-septic complications included one
catheter tip lying in the wrong position and another of extravasation of
chemotherapy.
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Out ofa total of48 catheter insertions, 18 were carried out without prophylactic
antibiotic cover (seven type A, seven type B, four type C). There was no
statistical difference in cumulative catheter survival between those who had
received prophylactic antibiotics (n=30) and those who had not (n=18) [log-
rank test, p>0.5]. Similarly, there was no statistical difference between the
number of septic episodes in the two subgroups, either in the initial four weeks
following the insertion (three episodes in the prophylactic antibiotic group as
opposed to two in the non-prophylactic group, X2=0.22, p>0.5) or overall (five
episodes compared to four X2=0.73, p>0.25). Comparison of the individual
lines was not possible because of the small numbers involved.
There were seven episodes of catheter related septicaemia caused by
Staphylococcus epidermidis, one episode of exit site infection caused by
Staphylococcus aureus and one episode of clinically suspicious line infection.
All the episodes of septicaemia secondary to catheter infection were caused by
coagulase negative staphylococci and despite treatmentwiththe mosteffective
antibiotics against these organisms (teicoplanin and vancomycin), four of the
catheters had to be removed. The one episode of exit site infection related to
Staphylococcus aureus responded rapidly to appropriate antibiotics.
Non-septic complications accounted for about 50% of the total complications.
The one episode of subclavian vein thrombosis required treatment with
thrombolytic agents and subsequent removal ofthe line, with delay in delivering
the next course of chemotherapy. The two cases of extravasation probably
occurred due to the needle either not being correctly positioned in the
subcutaneous reservoir or having slipped out from the reservoir during the
infusion. Both these patients were very ill and died within a short period of time
from othercauses unrelated to the extravasation. The two type A lines that were
accidentally withdrawn did not require replacement and the type C catheter,
whose tip lay in the internal mammary vein, had to be removed and replaced
before treatment could commence.
DISCUSSION
Central venous catheters have increased in popularity due to the improved
quality of life associated with them. Patients suffering from haematological
malignancies require frequent venepuncture both to monitor therapy and to
administer chemotherapeutic agents. Many ofthese agents cause phlebitis and
there is a high risk of extravasation of cytotoxic agents that may cause
considerable discomfort and even tissue necrosis. Because of these factors
central venous access is seen almost as an essential step before the patient
undergoes treatment. All the catheters are made ofsilicone rubber which is less
thrombogenic than other materials,5they can be inserted with relative ease
surgically and many agents and substances can be safely given through them.'
Patients find them acceptable, they are involved in the care of the lines in the
ward and at home and their quality of life is improved to a great extent, which
is an important factor for many of those whose long term outlook is not good.
The total number of complications at first sight appears to be high but
represents only 0.97 complications per100 catheter days overall. Sepsis is the
most common complication (0.49 per 100 catheter days) but there is
considerable variation in septic complications with the type of line inserted; the
type B and C being considerably lower than the type A catheters. Our results
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are reasonably comparable with those reviewed by Press et al6 and others.3' 7 8
The type Acatheter is inserted in patients who are more unwell to startwith and
undergoing intensive chemotherapy. It is also more susceptible to infection
because it is exposed externally and requires greater care and attention from
the patient. Many ofthe patients undergoing line insertions are very ill and may
have low blood counts. They can develop episodes of pyrexia, on the basis of
presumed infection, but blood cultures are often negative and there is no other
microbiological proof of sepsis other than response to empirically prescribed
antibiotics. The catheter may well be the source of sepsis in some of these
cases.
Most instances of catheter infection are caused by coagulase negative
Staphylococcus epidermidis,6 9' 10 with at least half the strains producing an
extra-cellular "glue" substancewhich causesadherence ofthe organismstothe
catheter wall and protects them from the action of antibiotics. Even the most
effective antibiotics against these strains are only effectual in up to one third of
cases. Once a central line is infected it may well have to be removed as
antibiotic treatment alone is not always successful - four out of8 (50%) in this
study. A study by Larson et al3 reported septicaemia in 38.3% of patients with
acute leukaemia who received type A lines and Hickman reports similarfigures
in marrow transplant patients1' - these results are similar to our own. There is
some evidence that prophylactic antibiotics given at the time of insertion have
a role in preventing later catheter related sepsis and in prolonging catheter
life.3'9 12 In our study we were unable to demonstrate any difference in
cumulative survival or septic complication rates following the introduction of
prophylactic teicoplanin but numbers are small and a larger randomised study
would be required.
Although sepsis represents the majority of complications seen with these
central catheters and is an important cause of morbidity, mortality appears to
bevery small and indeed, noneofthe patients diedfrom septicaemia secondary
to catheter infection. Other non-septic complications seen include damage to
thelines, venousthrombosis andblockingofthecatheters.Therearethrombolytic
agents available (urokinase) to unblock catheters and repair kits are available
for the repair of type A catheters.'3 Non-septic complications accounted for
about 50% of the total complications overall, and played an increasing role in
the lines less susceptible to septic complications. All complications are
associated with extra cost to the hospital in terms of additional medical and
nursing care, and therefore all possible precautions should be taken to attempt
to decrease the occurrence of these episodes. The non-septic complications
may be more amenable to prevention than the septic ones. The risk of
extravasation of chemotherapeutic agents can be minimized by carefully
checkingthatthe needle islying inthesubcutaneous reservoirandsubsequently
securing this firmly to prevent it from slipping out. Radiological assessment,
with the use of radio-contrast dye, can be used if doubt exists and this will also
reveal the position ofthe catheter tip. The risk of accidental withdrawal oftype
A catheters can be decreased by good patient education and ensuring that the
line is well secured.
Inconclusionthesecathetersimprovequalityoflifealthoughsepticcomplications
are a significant problem. Fortunately, the vast majority ofthese episodes can
be satisfactorily controlled with antibiotics. Increasing experience in the use of
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these catheters, both by patients and by medical/nursing staff, and further
improvement in the design and materials used in manufacture may lead to
reduction in septic complications in the future. The role of prophylactic
antibiotics requires further intensive investigation.
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